Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer

Disease site


Publication month/year

Jan 2018

Study question

To investigate whether the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery would improve outcomes among patients who were receiving neoadjuvant chemotherapy for stage III epithelial cancer.

Type of study

Multicenter, open-label, phase 3, randomized clinical trial (RCT)

Interventions compared

Interval cytoreductive surgery vs Interval cytoreductive surgery with HIPEC

Experimental arm (Intervention)

Interval cytoreductive surgery with HIPEC with cisplatin (100mg per square meter)

Control arm

Interval cytoreductive surgery

Primary outcome

Recurrence-free survival

Secondary outcome
  • Overall survival 
  • Side-effect profile
Inclusion criteria
  • Newly diagnosed stage III epithelial ovarian, fallopian tube, or peritoneal cancer who were referred for neoadjuvant chemotherapy
  • WHO performance status score of 0 to 2
  • Normal blood counts
  • Adequate renal function
Exclusion criteria

Cases that did not meet the inclusion criteria were excluded 

Intervention arm (Surgery-Plus-HIPEC group) Control arm (Surgery group)
Randomised (n) 122 123
Received treatment(n) 118 122
Recurrence-free survival 14.2 months 10.7 months
Overall survival 45.7 months 33.9 months
Adverse events of grade 3or4 27% 25%

The addition of Hyperthermic Intraperitoneal Chemotherapy to interval cytoreductive surgery resulted in longer recurrence-free survival and overall survival, and did not result in higher rates of side effects.

Reviewer name